Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Robert W. Baird
Robert W. Baird initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report released on Wednesday morning, Marketbeat reports. The brokerage issued an outperform rating and a $83.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on ITCI. Needham & Company LLC […]
More Stories
Verizon Communications (NYSE:VZ) Trading Down 0.3% – Time to Sell?
Shares of Verizon Communications Inc. (NYSE:VZ – Get Free Report) fell 0.3% on Friday . The company traded as low...
Target (NYSE:TGT) Trading 0% Higher – Still a Buy?
Target Co. (NYSE:TGT – Get Free Report) was up 0% during mid-day trading on Friday . The company traded as...
BAE Systems plc (OTCMKTS:BAESY) Sees Significant Growth in Short Interest
BAE Systems plc (OTCMKTS:BAESY – Get Free Report) was the recipient of a significant growth in short interest during the...
Spring Valley Acquisition Corp. II (NASDAQ:SVII) Short Interest Up 1,000.0% in December
Spring Valley Acquisition Corp. II (NASDAQ:SVII – Get Free Report) was the recipient of a large increase in short interest...
TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Up 65.4% in December
TC Biopharm (Holdings) Plc (NASDAQ:TCBP – Get Free Report) was the target of a significant increase in short interest in...
Spruce Biosciences, Inc. (NASDAQ:SPRB) Short Interest Up 613.4% in December
Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) was the target of a large increase in short interest in the...